NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
5 hedge funds and large institutions have $103K invested in NLS Pharmaceutics Warrant in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more ownership
Funds ownership: 3.02% → 3.02% (0%)
1% less capital invested
Capital invested by funds: $104K → $103K (-$1.26K)
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $52.6K | – | – | – |
|
|
ACM
2
Altium Capital Management
New York
| $21K | – | – | – |
|
|
AC
3
Ayrton Capital
Westport,
Connecticut
| $17.9K | – | – | – |
|
4
Hudson Bay Capital Management
Stamford,
Connecticut
| $10.5K | – | – | – |
|
|
CS
5
Clear Street
New York
| $905 | – | – | – |
|
NLSPW Hedge Fund Activity: Q3 2023 in Review
5 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q3 2023, worth a combined $103K — down 1.2% from $104K a quarter earlier.
Fund positioning in NLSPW was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
- 5 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $103K of NLS Pharmaceutics Warrant stock for Q3 2023, down 1.2% quarter-over-quarter.
- 0 funds opened new NLS Pharmaceutics Warrant positions in Q3 2023 and 0 closed out.
Based on aggregated 13F filings for Q3 2023.